A CDK4-selective inhibitor puts the brakes on cancer cells
Chang-Ching Lin1, Ariella B Hanker1
1Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
Cancer Cell
|March 11, 2025
Abstract:
In this issue of Cancer Cell, Palmer et al. describe the discovery and preclinical testing of the first-in-class CDK4-selective inhibitor atirmociclib. By sparing CDK6, atirmociclib has the potential to ameliorate dose-limiting hematological toxicities that limit drug exposure and treatment continuity and, by extension, the antitumor efficacy of dual CDK4/6 inhibitors.
Insights
Researchers discovered atirmociclib, a novel CDK4-selective inhibitor. This drug spares CDK6, potentially reducing toxicities and improving cancer treatment efficacy compared to dual CDK4/6 inhibitors.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cyclin-dependent kinases (CDKs) regulate the cell cycle.
- Dual CDK4/6 inhibitors are used in cancer therapy but cause dose-limiting toxicities.
- These toxicities, particularly hematological, limit treatment effectiveness.
Purpose of the Study:
- To report the discovery and preclinical evaluation of atirmociclib.
- To investigate atirmociclib as a selective inhibitor of CDK4.
- To assess the potential of CDK4 selectivity in mitigating toxicities associated with CDK inhibition.
Main Methods:
- Drug discovery and synthesis of atirmociclib.
- Biochemical assays to determine kinase selectivity (CDK4 vs. CDK6).
- Preclinical in vitro and in vivo models to assess efficacy and toxicity.
Main Results:
- Atirmociclib was identified as a first-in-class inhibitor selective for CDK4 over CDK6.
- Preclinical testing demonstrated potent antitumor activity.
- The selectivity profile suggests a potential for reduced hematological toxicities.
Conclusions:
- Atirmociclib represents a new therapeutic strategy targeting CDK4.
- Selective CDK4 inhibition may overcome limitations of current dual CDK4/6 inhibitors.
- Further clinical development is warranted to confirm safety and efficacy.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:39Positive Regulator Molecules
5.3K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.3K
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K